146 related articles for article (PubMed ID: 32171753)
1. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
van Dongen MGJ; Kok M
Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
[No Abstract] [Full Text] [Related]
2. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Guven DC; Taban H; Dizdar O
J Oncol Pharm Pract; 2022 Jan; 28(1):203-204. PubMed ID: 34628993
[No Abstract] [Full Text] [Related]
3. Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
Olivier T; Prasad V
Ann Oncol; 2023 Aug; 34(8):723-724. PubMed ID: 37423675
[No Abstract] [Full Text] [Related]
4. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
[TBL] [Abstract][Full Text] [Related]
5. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
Dent R; Rugo HS
Lancet Oncol; 2021 Jan; 22(1):27-28. PubMed ID: 33387495
[No Abstract] [Full Text] [Related]
6. [New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
Minot-This MS; Deleuze A
Bull Cancer; 2022 Oct; 109(10):988-989. PubMed ID: 35871860
[No Abstract] [Full Text] [Related]
7. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
8. Editorial for "Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer".
Pineda FD
J Magn Reson Imaging; 2021 Jul; 54(1):261-262. PubMed ID: 33974729
[No Abstract] [Full Text] [Related]
9. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
Shimoi T; Noguchi E; Sudo K; Chua YJ; Yonemori K
J Clin Oncol; 2021 Nov; 39(31):3519-3521. PubMed ID: 34554822
[No Abstract] [Full Text] [Related]
10. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of neoadjuvant chemotherapy combined with low-dose Apatinib in the treatment of triple negative breast cancer.
Yang JZ; Bao YF; Ci YJ; Zhu JJ
Asian J Surg; 2023 Jul; 46(7):2703-2704. PubMed ID: 36990815
[No Abstract] [Full Text] [Related]
12. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
13. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
Rizzo A; Palmiotti G
Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
[No Abstract] [Full Text] [Related]
15. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Steenbruggen TG; van Ramshorst MS; Kok M; Linn SC; Smorenburg CH; Sonke GS
Drugs; 2017 Aug; 77(12):1313-1336. PubMed ID: 28616845
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
17. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.
Laird J; Leventhal J; Kanowitz J; Damast S
Pract Radiat Oncol; 2021; 11(6):448-452. PubMed ID: 34157449
[TBL] [Abstract][Full Text] [Related]
18. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
20. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]